Publication | Open Access

Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-β1 in patients with grade 3 chronic degenerative joint disease of the knee

Tissue EngineeringRegenerative MedicineMusculoskeletal ResearchEngineeringCartilage DegenerationPreliminary ResultsBone RepairBiomedical EngineeringMedicinePhase IiOrthopaedic SurgeryGrade 3